²²³Ra-Radium Dichloride (²²³Ra-Xofigo® previously known as ²²³Ra-Alpharadin), is a ²²³Ra radioactive salt developed for the treatment of cancer types that commonly metastasize to the bone. While previous radio-therapeutics were used only for pain palliation, phase III trials of radium ²²³Ra dichloride demonstrated a positive effect on overall survival (OS), thereby establishing a truly therapeutic indication.

²²³Ra-Xofigo is approved for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.

²²³Ra mimics calcium and forms complexes with the bone mineral hydroxyapatite at areas of increased bone turnover, such as bone metastases.

The ALSYMPCA clinical trial (921 patients, 100 centers, 19 countries) that supported the US FDA and European EMA approval showed that ²²³Ra significantly reduced the risk of death by 30.5% compared to Placebo. This overall survival (OS) benefit was observed both in patients who were treated with the chemotherapy docetaxel prior to study enrollment and in those who were not. The study treatment consisted of six intravenous injections of ²²³Ra or Placebo each separated by an interval of 4 weeks. Median OS was 14.9 months with ²²³Ra plus best standard of care vs. 11.3 months with Placebo plus best standard of care.

Target/Mechanism: Bones

Carrier/Ligand: n/a

Radiation Type: Alpha particle (α)